Trial · NCT06305806
RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine)
NCT06305806, Phase 2, Completed, Kanecia Obie Zimmerman
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine). Trials, record NCT06305806. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06305806
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine)
- NCT number
- NCT06305806
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 181 participants, actual
- Lead sponsor
- Kanecia Obie Zimmerman
- Conditions
- Long COVID, Long Covid19, Long Covid-19
- Interventions
- Ivabradine, Ivabradine Placebo, Coordinated Care, Usual Care
- First posted
- 2024-03-12
- Last updated
- 2026-02-20
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Orthostatic Hypotension Questionnaire (OHQ)/Orthostatic Intolerance Questionnaire (OIQ) Composite Score | Baseline to End of Intervention (3 months) | The OHQ / OIQ is a measure of orthostatic intolerance and includes a 6-item symptom assessment (OHSA) and the 4-item Daily Activity Scale (OHDAS). Each item is scored from 0 (none/no interference) to 10 (worst possible/complete interference), describing the preceding week. The OHSA composite score is the average of the first 6 non-zero items and the OHDAS composite score is the average of the last 4 non-zero items. The OHQ/OIQ composite score is the average of the OHSA and OHDAS composite scores. The OHQ/OIQ scales at post-baseline are calculated using only those items that were included in the baseline scores. |
| Secondary | Change in Composite Autonomic Symptoms Score 31 (COMPASS-31) | Baseline to End of Intervention (3 months) | The COMPASS-31 is a patient reported outcome that measures autonomic symptoms across multiple domains commonly seen in patients with PASC. Scores range from 0-100 with higher values representing severe symptoms. |
| Secondary | Change in Malmo POTS Symptom Score | Baseline to End of Intervention (3 months) | The Malmo POTS symptom score assesses symptom burden in postural orthostatic tachycardia syndrome (POTS). It is a self-rating, 12-item score (0-10 per item, total range 0-120) based on patients' own perception of symptoms through visual analogue scale assessment. Higher scores represent more pronounced symptoms. |
| Secondary | Change in heart rate (HR) | Baseline to End of Intervention (3 months) | measured during Active Stand Test |
| Secondary | Change in 6-min Walk Test | Baseline to End of Intervention (3 months) | Normal walking speed will be measured using a standard 6 minute walk |
| Secondary | Change in PROMIS-29 + 2 Questionnaire | Baseline to End of Intervention (3 months) | The PROMIS-29 consists of 29 items that assess general domains of health and functioning, including overall physical health, mental health, social health, pain, fatigue, and overall perceived quality of life. The PROMIS-29+2 is used to calculate a preference score (PROPr) by the addition of two Cognitive Function Ability items. Scores will be reported as T scores ranging from 0 to 100, with a score of 60 being 1 standard deviation above the mean. Higher scores indicate worse overall health. |
| Secondary | Characterize the safety and tolerability of study intervention for treatment of PASC | Baseline to Follow-up (6 months) | Adverse events, including serious adverse events (SAEs) and events of special interest (ESIs). Proportion of participants who experience individual SAEs and the proportion who experience any one or more SAEs. Incidence of SAEs leading to discontinuation. Incidence of ESIs. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 41720282 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06305806
GET https://conductscience.org/api/trials/v1/NCT06305806/registered